Abstract
Introduction: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease causing bile duct destruction and inflammation, impacting patient’s quality of life (QoL) due to variable symptoms. Digital symptom-tracker apps may improve patient care through enhanced monitoring. This study reassessed symptom burden in PBC patients using a tailored symptom-tracker app, focusing on its usability, effectiveness, and impact on management and QoL. Methods: Based on Kautz5 gUG “Symptomtracker,” our app in REDCap allowed users to log PBC symptoms over 4 weeks, alongside medication use. Ethics approval and data security complied with German regulations. User feedback was incorporated for better usability. Symptom data were standardized, and R software was used for descriptive statistics and Chi-square tests. Results: From March 2023 to October 2024, 210 patients (190 female, 20 male) were enrolled, median age 51 years. Among 90 patients who completed the questionnaire, fatigue was most prevalent (87.8%), followed by joint pain (80%), concentration difficulties (74.4%), abdominal discomfort (70%), and sicca symptoms. Other common symptoms were leg cramps (50%) and swollen feet (40%); jaundice was rare (7.8%). Older patients, especially those aged 50–60, reported a higher symptom burden, but Chi-square tests showed no significant differences across age or gender. Conclusion: This study highlights a significant symptom burden in PBC, particularly fatigue and joint pain. While older patients reported more symptoms, no significant differences were observed by age or gender. The symptom-tracker app enhanced monitoring and patient engagement, showing the potential of digital tools in PBC management. Further research is needed to evaluate long-term impacts.
Journal Section:
Liver
References
1.
Lleo
A
, Wang
G-Q
, Gershwin
ME
, Hirschfield
GM
. Primary biliary cholangitis
. Lancet Lond Engl
. 2020
;396
(10266
):1915
–26
. 2.
Boonstra
K
, Kunst
AE
, Stadhouders
PH
, Tuynman
HA
, Poen
AC
, van Nieuwkerk
KMJ
, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study
. Liver Int
. 2014
;34
(6
):e31
–38
. 3.
Gazda
J
, Drazilova
S
, Janicko
M
, Jarcuska
P
. The epidemiology of primary biliary cholangitis in European countries: a systematic review and meta-analysis
. Can J Gastroenterol Hepatol
. 2021
;2021
:9151525
. 4.
Galoosian
A
, Hanlon
C
, Zhang
J
, Holt
EW
, Yimam
KK
. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches
. J Clin Transl Hepatol
. 2020
;8
(1
):49
–60
. 5.
Langenbacher
D
, Kautz
A
, Trautwein
C
, Schwenke
C
, Sankawa
Y
, Kremer
AE
. THU-122 patient-reported insights on current care practices for primary biliary cholangitis, quality of life and self-management: results of the German PBC online survey
. J Hepatol
. 2024
;80
:S320
. 6.
Mayo
MJ
, Carey
E
, Smith
HT
, Mospan
AR
, McLaughlin
M
, Thompson
A
, et al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis
. Dig Dis Sci
. 2023
;68
(3
):995
–1005
. 7.
Mosher
VAL
, Swain
MG
, Pang
JXQ
, Kaplan
GG
, Sharkey
KA
, MacQueen
GM
, et al. Primary biliary cholangitis alters functional connections of the brain’s deep gray matter
. Clin Transl Gastroenterol
. 2017
;8
(7
):e107
. 8.
Montali
L
, Gragnano
A
, Miglioretti
M
, Frigerio
A
, Vecchio
L
, Gerussi
A
, et al. Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison
. J Transl Autoimmun
. 2021
;4
:100081
. 9.
Lynch
EN
, Campani
C
, Innocenti
T
, Dragoni
G
, Biagini
MR
, Forte
P
, et al. Understanding fatigue in primary biliary cholangitis: from pathophysiology to treatment perspectives
. World J Hepatol
. 2022
;14
(6
):1111
–9
. 10.
Mells
GF
, Pells
G
, Newton
JL
, Bathgate
AJ
, Burroughs
AK
, Heneghan
MA
, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study
. Hepatol Baltim Md
. 2013
;58
(1
):273
–83
. 11.
Newton
JL
, Gibson
GJ
, Tomlinson
M
, Wilton
K
, Jones
D
. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence
. Hepatol Baltim Md
. 2006
;44
(1
):91
–8
. 12.
van Ginneken
BTJ
, van den Berg-Emons
RJG
, van der Windt
A
, Tilanus
HW
, Metselaar
HJ
, Stam
HJ
, et al. Persistent fatigue in liver transplant recipients: a two-year follow-up study
. Clin Transpl
. 2010
;24
(1
):E10
–16
. 13.
Gungabissoon
U
, Smith
HT
, von Maltzahn
R
, Logie
J
, Fairburn-Beech
J
, Ma
L
, et al. Pruritus in primary biliary cholangitis is under-recorded in patient medical records
. BMJ Open Gastroenterol
. 2024
;11
(1
):e001287
. 14.
Hegade
VS
, Mells
GF
, Fisher
H
, Kendrick
S
, DiBello
J
, Gilchrist
K
, et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom
. Clin Gastroenterol Hepatol
. 2019
;17
(7
):1379
–87.e3
. 15.
European Association for the Study of the Liver
. EASL clinical practice Guidelines: management of cholestatic liver diseases
. J Hepatol
. 2009
;51
(2
):237
–67
. 16.
Corpechot
C
, Chazouillères
O
, Poupon
R
. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome
. J Hepatol
. 2011
;55
(6
):1361
–7
. 17.
Rishe
E
, Azarm
A
, Bergasa
NV
. Itch in primary biliary cirrhosis: a patients’ perspective
. Acta Derm Venereol
. 2008
;88
(1
):34
–7
. 18.
Talwalkar
JA
, Donlinger
JJ
, Gossard
AA
, Keach
JC
, Jorgensen
RA
, Petz
JC
, et al. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial
. Dig Dis Sci
. 2006
;51
(11
):1985
–91
. 19.
Saffioti
F
, Gurusamy
KS
, Eusebi
LH
, Tsochatzis
E
, Davidson
BR
, Thorburn
D
. Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis
. Cochrane Database Syst Rev
. 2017
;3
(3
):CD011648
. 20.
Younossi
ZM
, Bernstein
D
, Shiffman
ML
, Kwo
P
, Kim
WR
, Kowdley
KV
, et al. Diagnosis and management of primary biliary cholangitis
. Am J Gastroenterol
. 2019
;114
(1
):48
–63
. 21.
European Association for the Study of the Liver
. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis
. J Hepatol
. 2017
;67
(1
):145
–72
. 22.
Kuo
A
, Kuo
A
, Bowlus
CL
. Management of symptom complexes in primary biliary cholangitis
. Curr Opin Gastroenterol
. 2016
;32
(3
):204
–9
. 23.
Quarneti
C
, Muratori
P
, Lalanne
C
, Fabbri
A
, Menichella
R
, Granito
A
, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis
. Liver Int
. 2015
;35
(2
):636
–41
. 24.
Qudah
B
, Luetsch
K
. The influence of mobile health applications on patient - healthcare provider relationships: a systematic, narrative review
. Patient Educ Couns
. 2019
;102
(6
):1080
–9
. 25.
Harris
PA
, Swafford
J
, Serdoz
ES
, Eidenmuller
J
, Delacqua
G
, Jagtap
V
, et al. MyCap: a flexible and configurable platform for mobilizing the participant voice
. JAMIA Open
. 2022
;5
(2
):ooac047
. 26.
Harris
PA
, Taylor
R
, Thielke
R
, Payne
J
, Gonzalez
N
, Conde
JG
. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support
. J Biomed Inform
. 2009
;42
(2
):377
–81
. 27.
Debon
R
, Coleone
JD
, Bellei
EA
, De Marchi
ACB
. Mobile health applications for chronic diseases: a systematic review of features for lifestyle improvement
. Diabetes Metab Syndr
. 2019
;13
(4
):2507
–12
. 28.
Trivella
J
, John
BV
, Levy
C
. Primary biliary cholangitis: epidemiology, prognosis, and treatment
. Hepatol Commun
. 2023
;7
(6
):e0179
. 29.
Newton
JL
, Hollingsworth
KG
, Taylor
R
, El-Sharkawy
AM
, Khan
ZU
, Pearce
R
, et al. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology
. Hepatology
. 2008
;48
(2
):541
–9
. 30.
Shamshtein
D
, Liwinski
T
. Pathogenesis and management of fatigue in primary biliary cholangitis
. Health Behav
. 2022
;10
(1
):1
–25
. 31.
Watt
M
, Hyde
A
, Spence
JC
, Wright
GM
, Vander Well
S
, Johnson
E
, et al. The feasibility and acceptability of an online mind-body wellness program for patients with primary biliary cholangitis
. Can Liver J
. 2023
;6
(3
):314
–31
. 32.
Sivakumar
T
, Kowdley
KV
. Anxiety and depression in patients with primary biliary cholangitis: current insights and impact on quality of life
. Hepat Med
. 2021
;13
:83
–92
. 33.
Zenouzi
R
, von der Gablentz
J
, Heldmann
M
, Göttlich
M
, Weiler-Normann
C
, Sebode
M
, et al. Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure
. PloS One
. 2018
;13
(1
):e0190005
. 34.
Phaw
NA
, Dyson
JK
, Mells
G
, Jones
D
. Understanding fatigue in primary biliary cholangitis
. Dig Dis Sci
. 2021
;66
(7
):2380
–6
. 35.
Huet
PM
, Deslauriers
J
, Tran
A
, Faucher
C
, Charbonneau
J
. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis
. Am J Gastroenterol
. 2000
;95
(3
):760
–7
. 36.
Jones
DEJ
, Bhala
N
, Burt
J
, Goldblatt
J
, Prince
M
, Newton
JL
. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort
. Gut
. 2006
;55
(4
):536
–41
. 37.
Jones
DE
, Al-Rifai
A
, Frith
J
, Patanwala
I
, Newton
JL
. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up
. J Hepatol
. 2010
;53
(5
):911
–7
. 38.
Gershwin
ME
, Selmi
C
, Worman
HJ
, Gold
EB
, Watnik
M
, Utts
J
, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients
. Hepatology
. 2005
;42
(5
):1194
–202
. 39.
Selmi
C
, Gershwin
ME
, Lindor
KD
, Worman
HJ
, Gold
EB
, Watnik
M
, et al. Quality of life and everyday activities in patients with primary biliary cirrhosis
. Hepatol Baltim Md
. 2007
;46
(6
):1836
–43
. 40.
Marasini
B
, Gagetta
M
, Rossi
V
, Ferrari
P
. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients
. Ann Rheum Dis
. 2001
;60
(11
):1046
–9
. 41.
Trivedi
PJ
. Risk stratification in primary sclerosing cholangitis: it’s time to move on from replicating imperfection and break the glass ceiling
. J Hepatol
. 2019
;71
(5
):867
–70
. 42.
Hegade
VS
, Mells
GF
, Lammert
C
, Juran
B
, Lleo
A
, Carbone
M
, et al. P1152: a comparative study of pruritus in PBC cohorts from UK, USA and Italy
. J Hepatol
. 2015
;62
:S785
. 43.
Carbone
M
, Sharp
SJ
, Flack
S
, Paximadas
D
, Spiess
K
, Adgey
C
, et al. The UK‐PBC risk scores: derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis
. Hepatology
. 2016
;63
(3
):930
–50
. 44.
Lleo
A
, Jepsen
P
, Morenghi
E
, Carbone
M
, Moroni
L
, Battezzati
PM
, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis
. Sci Rep
. 2016
;6
(1
):25906
. 45.
Invernizzi
P
. Geoepidemiology of autoimmune liver diseases
. J Autoimmun
. 2010
;34
(3
):J300
–06
. 46.
Podda
M
, Selmi
C
, Lleo
A
, Moroni
L
, Invernizzi
P
. The limitations and hidden gems of the epidemiology of primary biliary cirrhosis
. J Autoimmun
. 2013
;46
:81
–7
. 47.
Ma
D
, Ma
J
, Zhao
C
, Tai
W
. Reasons why women are more likely to develop primary biliary cholangitis
. Heliyon
. 2024
;10
(4
):e25634
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
